An interventional study of One Stop Management and Usual care management in Stroke Acute, Acute Ischemic Stroke AIS and Hemorrhagic Stroke, Intracerebral, sponsored by Prof. Dr. Jan Liman. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Prof. Dr. Jan Liman · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hemorrhagic Stroke with a site in Germany — 3 open to participants now, 5 under way, none of them phase 3. Hemorrhagic Stroke · Germany.
Among the 14 studies in Hemorrhagic Stroke with a site in Germany, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 5 with no phase, and was the 14th registered.
234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.
Browse Hemorrhagic Stroke studies →3 of the 14 studies in Hemorrhagic Stroke with a site in Germany are open now. Recruiting first, the newest first:
Wandercraft · Sites in Germany, France, Spain
Ages 18+
University Hospital, Basel, Switzerland · Sites in Germany, United States, Argentina and 6 more countries
Ages 18+ · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 390 is above the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.
Median enrollment 380 across the 11 interventional studies, 736 across the 3 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 9 most frequent:
This is the only study on the registry with Prof. Dr. Jan Liman as lead sponsor.
Prof. Dr. Jan Liman has 1 study filed under Hemorrhagic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hemorrhagic Stroke with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Stroke, especially acute ischemic stroke (AIS) caused by a blocked blood vessel in the brain, is a leading cause of death and long-term disability. When the blockage is in a large blood vessel, a procedure called endovascular therapy (EVT)-where the clot is removed using a catheter-is highly effective. However, the sooner EVT is done, the better the outcome for the patient.
Research has shown that delays between arriving at the hospital and starting EVT (called door-to-groin time) significantly reduce the chances of recovery. For example, reducing this time by just 15 minutes can mean 20 more patients (out of 1,000 treated) going home instead of to a care facility. Even a 10-minute improvement can result in over 100 extra days of independent living for patients and save more than $10,000 in healthcare costs per patient.
To reduce these delays, hospitals have improved stroke workflows. In the current standard approach, patients suspected of having a stroke are taken first to a CT scan room to confirm the diagnosis, and then, if a treatable occlusion is found, to a separate room for EVT. This usually takes around 60-70 minutes.
However, moving patients between rooms takes time. A new approach called "One-Stop management" could solve this. In this method, both the brain scan and the EVT procedure are done in one room-the angiography suite-using special imaging tools called flat panel CT (FDCT) and FDCT angiography (FDCT-A).
A previous study with 230 patients showed that One-Stop management is possible and saves time. But there's a challenge: the decision to follow the One-Stop pathway is made before a clear diagnosis is available. That's important because not all strokes benefit from EVT. Severe stroke symptoms (measured by a score called NIHSS ≥10) can come from:
To do this, the GET-FAST trial will compare the One-Stop approach to the standard two-room process. Patients will be randomly assigned to one of the two strategies. Importantly, this randomization won't affect their actual treatment-everyone will still receive the best care according to current medical guidelines. The main endpoint for the evaluation of the One-Stop approach will be long-term (at 90 days) disability and dependency in daily life as measured with the modified Rankin Scale (mRS).
This study will include all patients as they were assigned, regardless of what type of stroke they actually had. This is called an "intention-to-treat" analysis, and it provides the most reliable measure of the overall impact of One-Stop management.
Another key aspect of the trial is that any CE-certified imaging system already used in hospitals can be used for the One-Stop process-no specific brand or model is required. This makes the results more applicable to real-world hospital settings.
If GET-FAST proves that One-Stop management leads to better patient outcomes, this could transform how stroke care is delivered. More patients could return to independent living, and fewer would require long-term care -leading to major reductions in healthcare costs. For example, even a one-point improvement on a common stroke disability scale (mRS) can triple the savings in lifetime care costs.
234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.
This study's planned enrollment of 390 is above the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.
Browse Hemorrhagic Stroke studies →This is the only study on the registry with Prof. Dr. Jan Liman as lead sponsor.
Compared within Hemorrhagic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients within the intervention group will be transported directly after randomization to the angiography room.
Other: One Stop Management
Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A.
Other: Usual care management
Patients within the intervention group will be transported directly after randomization to the angiography room. In the angiography room diagnostic imaging will be performed using cranial non-contrast FDCT and FDCT-A with subsequent EVT (if a treatable vessel occlusion was identified). Therefore, diagnostics and treatment will be performed in the same room (One-Stop management). Only patients with a treatable occlusion will undergo arterial puncture.
Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A. IVT will be given directly in the MDCT room if no contraindication is present. If on diagnostic imaging a treatable vessel occlusion was identified, the patient will be transported to the angiography room, where EVT will be performed.
Degree of Dependency and disability in daily activities
As assessed with the modified Rankin Scale (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).
Time frame: 90 days (+/- 15 days) after randomization
Early neurological improvement
Early neurological improvement is defined as a decrease of at least 4 points on the National Institute of Health Stoke Scale (NIHSS) compared to baseline; range of NIHSS 0 - 42 with higher values indicating more severe neurological deficit
Time frame: 5 - 7 days after randomization or discharge if earlier
Early neurological deterioration
Early neurological deterioration is defined as an increase of at least 4 points on National Institutes of Health Stroke Scale compared to baseline, death or persistent coma; range of NIHSS 0 - 42 with higher values indicating more severe neurological deficit
Time frame: 5 - 7 days after randomization or discharge if earlier
Independent functional outcome
Defined as a modified Rankin Scale of 0 to 2 (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).
Time frame: 90 days (+ / - 15 days) after randomization
Cognitive function
As assessed with the Montreal Cognitive Assessment Test (MoCA); range 0 - 30 with lower values indicating more severe cognitive impairment
Time frame: 90 days (+/- 15 days) after randomization
Health-related quality of life
As assessed with the Euro-Qol 5d; 5 point scale with higher values indicating better quality of life in the specific domain
Time frame: 90 days (+/- 15 days) after randomization
Degree of Dependency and disability in daily activities
As assessed with the modified Rankin Scale (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).
Time frame: 365 days (+/- 30 days) after randomization
Health-related quality of life
As assessed with the Euro-QoL-5D; 5 point scale with higher values indicating better quality of life in the specific domain
Time frame: 365 days (+/- 30 days) after randomization
Cognitive function
As assessed with the telephone Montreal Cognitive Assessment Test (T-MoCA); range 0 - 22 with lower values indicating more severe cognitive impairment
Time frame: 365 days (+/- 30 days) after randomization
Safety: Symptomatic intracranial hemorrhage
All intracerebral hemorrhages will be classified by the blinded Core Lab according to the Heidelberg Bleeding Classification. Symptomatic intracerebral hemorrhage (sICH) will be defined using a modified SITS-MOST definition: sICH is defined as the presence of a parenchymal hemorrhage type 2 (local or remote), subarachnoid hemorrhage, and/or intraventricular hemorrhage on imaging performed 24 hours post-treatment (±12 hours), in combination with one of the following: A neurological deterioration of ≥4 points on the National Institute of Health Stroke Scale (NIHSS; ranging from 0 - 42 with higher values indication more severe neurological deficit) from baseline, or from the lowest NIHSS value between baseline and 24 hours; persistent coma; or Death.
Time frame: Within 24 hours (+/- 12 hours) after randomization
Safety: Serious Adverse Events
Time frame: Within 90 days after randomization
Safety: Mortality
All-cause mortality
Time frame: Within 90 days after randomization
Plan to share: Yes — All IPD collected throughout the trial
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Beginning 3 years after publication of the main results with no end date.
Access criteria: A proposal that describes the planned analyses shall be submitted to the sponsor-investigator of the trial.
Started Dec 2025 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.
Of 75 non-industry interventional studies with no phase under Hemorrhagic Stroke, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 31 months is below that.
Counting every sponsor, half of 89 studies reached it within 36 months; a quarter within 14 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.